Although ghrelin therapy resulted in a shorter duration of SIRS, a lower postoperative level of CRP, and a decrease in the total percentage of bodyweight loss, it did not affect the risk of morbidity outcomes such as pulmonary complications, wound complications, anastomotic leak, or arrhythmia. The gene discussed is CRP; the disease is cardiac arrhythmia.